Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Sanofi

Novavax (NASDAQ:NVAX) shares rocketed 40% in premarket trading Friday, driven not only by the company's fiscal Q1 2024 earnings report but more significantly, by a crucial multi-billion dollar deal with French pharmaceutical giant Sanofi SA. Despite reporting a first-quarter loss per share of $1.05, wider than the $0.92 anticipated by analysts, and revenue of $93.

Novavax shares jump 40% on $1.2 billion licensing deal with Sanofi despite Q1 losses

Novavax on Friday said it had struck a $1.4 billion deal with Sanofi to commercialize its existing COVID-19 vaccine and develop a new combined jab to inoculate against both the coronavirus and influenza, in a major boost to struggling biotech company.

Novavax shares surge on new $1.4 billion deal with Sanofi

COVID-19 vaccine maker Novavax , on Friday, erased doubts about its ability to remain in business by removing a so-called "going concern" notice.

Novavax erases doubts about its ability to remain in business

Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-MTM adjuvant This agreement represents a potential multi-billion dollar revenue opportunity for Novavax including : $500 million upfront payment Approximately $70 million equity investment in Novavax Up to $700 million in COVID-19 and combination product near-term milestones, plus ongoing tiered royalties on product sales Up to $200 million in milestones plus royalties for each new vaccine developed utilizing Novavax's Matrix-M TM  adjuvant Announces addition of standalone influenza vaccine to Phase 3 COVID-19-Influenza Combination vaccine trial, which is on-track to initiate second half of 2024, with potential 2026 launch for both candidates Reduced current liabilities by an additional $831 million during Q1 2024 Achieved total revenue in Q1 2024 of $94 million Novavax removes going concern notice Company to host conference call today at 8:30 a.m. ET GAITHERSBURG, Md.

Novavax Reports First Quarter 2024 Financial Results and Operational Highlights

Sanofi on Friday announced it has reached a 'co-exclusive' licensing agreement with Novavax to sell a stand-alone COVID-19 vaccine and develop new flu-COVID-19 combination vaccines.

France's Sanofi in COVID-19 vaccine deal with Novavax - statement

The deal will allow Novavax to lift its "going concern" warning, which it first issued in 2023 due to having "substantial doubt" about its ability to survive.

Novavax signs multibillion-dollar deal with Sanofi to commercialize Covid vaccine, develop combination shots

Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards Provides Novavax with cash and an equity investment totalling approximately $1.2 billion (upfront payment of $500 million and up to $700 million in additional development, regulatory and launch milestones), plus tiered royalties Novavax is entitled to additional launch and sales milestone opportunities of up to $200 million, plus mid-single digit royalties, for each additional Sanofi vaccine product developed under a non-exclusive license with Novavax's Matrix-M™ adjuvant technology Accelerates potential for development of a novel COVID-19-Influenza combination product based on authorized vaccines with demonstrated efficacy and tolerability, potentially offering individuals enhanced convenience and protection GAITHERSBURG, Md. , May 10, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, has entered into a co-exclusive licensing agreement with Sanofi (Nasdaq: SNY).

Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines

Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

Plug Power

Petco Health and Wellness

Although Wall Street is captivated by the artificial intelligence (AI) revolution, Nvidia's upside may be limited. Select Wall Street analysts expect far superior returns from three high-risk/high-reward small-cap companies.

Forget Nvidia: These 3 Small-Cap Stocks Offer Up to 557% Upside, According to Select Wall Street Analysts

Novavax (NVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Novavax (NVAX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

GAITHERSBURG, Md. , May 7, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its first quarter 2024 financial results and operational highlights at 8:30 a.m.

Novavax to Host Conference Call to Discuss First Quarter 2024 Financial Results and Operational Highlights on May 10, 2024

Hedge fund Shah Capital on Monday urged Novavax shareholders to vote against the re-election of three directors and proposals related to executive compensation, ramping up its efforts for a board shakeup at the COVID-19 vaccine maker.

Novavax's top shareholder Shah Capital ramps up efforts for board shakeup

In the latest trading session, Novavax (NVAX) closed at $4.33, marking a +0.93% move from the previous day.

Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know

Aurora Cannabis

Chegg

Novavax is going nowhere in the COVID-19 market, or any other market. Chegg's business is becoming irrelevant in the age of artificial intelligence.

3 Beaten-Down Stocks I Wouldn't Touch With a 10-Foot Pole

BioMarin Pharmaceutical

Halozyme Therapeutics

If you have a high tolerance for volatility then the biotech sector might be for you. Biotech stocks can range from pre-revenue startups to global pharmaceutical giants.

3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition

Iovance Biotherapeutics

Bull markets favor growth stocks, and that means many biotech players could benefit. Wall Street believes in the potential of these two biotech innovators.

These Biotech Stocks Could Soar 120% and 295%, According to Wall Street

U.S.-based hedge fund Shah Capital on Monday recommended the appointment of two new independent directors to the Novavax board.

Hedge fund Shah Capital recommends two new candidates for Novavax board

Hedge fund Shah Capital on Monday called for an “urgent shake up” at the board of Novavax over claims its management has failed to capitalize on safety concerns surrounding mRNA vaccines to boost sales of its own non-mRNA COVID-19 vaccine.

Novavax failed to capitalize on fears surrounding mRNA vaccines, activist investor says

bluebird bio

Bluebird Bio's most recently approved gene editing therapy looks highly promising. Novavax has generated decent revenue from its coronavirus vaccine.

Better Buy: Bluebird Bio Vs. Novavax

Novavax's business still centers heavily around COVID-19. This year, it expects up to $1 billion in revenue.

Down 60% From Its 52-Week High, Is Novavax Stock a Buy?

To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.

Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?

Blink Charging

Cardiff Oncology

Hive Blockchain Technologies Ltd

Riot Blockchain

Vaxart

The 2024 presidential election is shaping up to be just as exciting and contentious the 2020 contest. That's because it looks to be a rematch between President Biden and former President Trump.

Election Year Encore: Can 2020's Top 7 Stock Winners Repeat Their Performance in 2024?

Teladoc

Teladoc's position in the growing telemedicine industry could help it turn things around. Novavax's only approved product is going nowhere and its pipeline has too little to offer.

1 Beaten-Down Stock to Buy and 1 to Avoid Like the Plague

GAITHERSBURG, Md. , April 1, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will showcase continued progress on data from its updated COVID-19 vaccine (NVX-CoV2601) and provide an overview of its influenza and COVID-19-Influenza Combination (CIC) vaccine candidates at the World Vaccine Congress 2024 (WVC) in Washington, DC, April 2 to 4, 2024.

Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024

Investing in biopharmaceutical stocks comes with more risks than some other types of stocks.

News for Novavax Stock (NVAX)